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Background: Recently, regulatory T (Treg) cells have gained interest in the fields of immunopathology, transplantation
and oncoimmunology. Here, we investigated the microRNA expression profile of human natural CD8+CD25+ Treg cells
and the impact of microRNAs on molecules associated with immune regulation.
Methods: We purified human natural CD8+ Treg cells and assessed the expression of FOXP3 and CTLA-4 by flow
cytometry. We have also tested the ex vivo suppressive capacity of these cells in mixed leukocyte reactions. Using
TaqMan low-density arrays and microRNA qPCR for validation, we could identify a microRNA ‘signature’ for
CD8+CD25+FOXP3+CTLA-4+ natural Treg cells. We used the ‘TargetScan’ and ‘miRBase’ bioinformatics programs to
identify potential target sites for these microRNAs in the 3′-UTR of important Treg cell-associated genes.
Results: The human CD8+CD25+ natural Treg cell microRNA signature includes 10 differentially expressed microRNAs.
We demonstrated an impact of this signature on Treg cell biology by showing specific regulation of FOXP3, CTLA-4
and GARP gene expression by microRNA using site-directed mutagenesis and a dual-luciferase reporter assay.
Furthermore, we used microRNA transduction experiments to demonstrate that these microRNAs impacted their
target genes in human primary Treg cells ex vivo.
Conclusions: We are examining the biological relevance of this ‘signature’ by studying its impact on other important
Treg cell-associated genes. These efforts could result in a better understanding of the regulation of Treg cell function
and might reveal new targets for immunotherapy in immune disorders and cancer.
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Regulatory T (Treg) cells are specialized subsets of T cells
that modulate the immune system to avert unwanted im-
mune responses, maintain immunological self-tolerance
and homeostasis, dampen inflammatory responses, and
limit tissue damage. Treg cells can be divided into natural
and adaptive Treg cells. Natural Treg cells develop in the
thymus and express both CD25 and FOXP3. Adaptive
Treg cells develop in the periphery following antigenic (by
self- or foreign-antigen) stimulation in the presence of
specific immunomodulatory molecules. Moreover, Treg* Correspondence: mrouas@ulb.ac.be
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unless otherwise stated.cells can also be divided into two classes, CD4+ and CD8+
Treg cells [1].
CD8+ T cells play a major role as adaptive effectors in
several immunopathological conditions, such as auto-
immune disease [2-6], transplantation [7,8], host defense
and cancer [8,9]. Despite the long-held notion that CD8+
T cells could mediate suppression, most reports have fo-
cused on the regulatory properties of CD4+ T cell subsets
and only a few studies have characterized CD8+ T cell-
mediated immune regulation. The main reason for the
relative neglect of CD8+ Treg cells by researchers is the
absence of markers that allow their identification. Re-
cently, several subsets of CD8+ Treg cells have been iden-
tified based on the expression of CD25, CD56 [10],
FOXP3, CXCR3, LAG-3, CD103, CD122 and/or HLA-G,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Jebbawi et al. Journal of Translational Medicine 2014, 12:218 Page 2 of 16
http://www.translational-medicine.com/content/12/1/218as well as the absence of CD28 expression. These di-
verse subpopulations of CD8+ Treg cells have different
mechanisms of suppression and play roles in cancer, in-
fection, transplantation and autoimmunity [11-25].
Natural CD8+ Treg cells include CD8+CD25+ T cells,
which share functional and phenotypic similarities with
CD4+CD25+ Treg cells, such as CTLA-4, GITR and
intracellular Foxp3 expression. CD8+CD25+ Treg cells
can suppress CD4+CD25− T cells in a membrane-bound
TGFβ and CTLA-4-mediated contact-dependent man-
ner that induces IL-2Rα downregulation on target T
cells [19]. They can also act by producing immunosup-
pressive cytokines, such as TGF-β and IL-10 [26], or by
inactivating dendritic cells [21]. Moreover, naturally oc-
curring human CD8+CXCR3+ T cells have been shown
to secrete IL-10 and suppress IFN-γ production, in a
manner similar to murine CD8+CD122+ Treg cells [27].
FOXP3 has emerged as a marker for T cells with regu-
latory activity. Deletion or mutation of FOXP3 is associ-
ated with the lymphoproliferative disorder that occurs in
scurfy mice and immunodysregulation, polyendocrinopa-
thy, enteropathy, X-linked (IPEX) syndrome in humans
[28-30]. As a ‘master transcription factor’, FOXP3 is a crit-
ical regulator of CD4+CD25+ Treg cell development and
function, and appears to be the best marker to identify
natural CD4+ Treg cells [31,32]. However, despite being
the most specific marker of Treg cells, together with ele-
vated expression of the high-affinity IL-2 receptor-α chain
(CD25), FOXP3 cannot be used to isolate viable Treg cells
because of its intracellular expression.
Although we still lack specific markers, many cell-
surface molecules have been reported to characterize
human Treg cells, such as expression of glucocorticoid-
induced tumor necrosis factor receptor (GITR), CD62
ligand (CD62L), OX40 (CD134), cytotoxic T-lymphocyte
antigen-4 (CTLA-4), and low expression of IL-7 receptor
(CD127) [33-35] and glycoprotein A repetitions predom-
inant (GARP) [36]. CTLA-4 is known to be a critical
regulator of immune responses by reducing T cell activa-
tion and proliferation. CD4+ Treg cells are known to
constitutively express CTLA-4 [33]. Polymorphisms in
CTLA-4 have been associated with several autoimmune
diseases, including systemic lupus erythematosus and
insulin-dependent diabetes mellitus; a general suscepti-
bility to autoimmune diseases has also been described
for CTLA-4 polymorphisms [37-39], emphasizing its
pivotal role in immune tolerance.
GARP appears to be a crucial membrane-anchored re-
ceptor for latent TGF-β on the Treg cell surface [40,41].
GARP expression has been shown to identify selectively
activated human FOXP3+ Treg cells and to play a role in
Treg cell-mediated immunosuppression [36].
The microRNAs (miRNAs) are an abundant class of
evolutionarily conserved small non-coding RNAs thatregulate gene expression post-transcriptionally by affect-
ing the degradation and translation of target mRNA
transcripts. The biogenesis of miRNAs involves several
processing steps that have mostly been defined in cell-
based and biochemical studies. Primary miRNA tran-
scripts are first processed into precursor microRNA
(pre-miRNA) by the nuclear RNase III enzyme Drosha
[42-45]. These pre-miRNAs are then actively transported
by Exportin-5 to the cytoplasm, where they are further
processed by the cytoplasmic RNase III enzyme Dicer
[46-48]. The functional miRNA strand is then selectively
loaded into the RNA-induced silencing complex (RISC)
[49,50]. Mature miRNAs then guide the RISC to cog-
nate target genes, and target gene expression is re-
pressed by either destabilizing the target mRNAs or
repressing their translation. To date, a rapidly growing
number of miRNAs have been identified in mammalian
cells and shown to be involved in a range of physio-
logical responses, including development, differenti-
ation and homeostasis [51-53].
Recent publications have provided compelling evidence
that miRNAs are highly expressed in Treg cells, and that
the expression of Foxp3 is controlled by miRNAs. Among
miRNAs, miR-21, −24, −31, −95, −210 [51] and −155 [54]
affect Foxp3 expression, and miR-155 is an important
regulator of lymphocyte function and homeostasis. Other
studies have shown that miRNAs are involved in the regu-
lation of T cell function. For example, miR-142-3p can
regulate GARP expression in CD4+CD25+ T cells [55].
Huang et al. showed an indirect effect of miR-142-3p
on FOXP3 expression by targeting AC9 mRNA [56].
Moreover, miR-17-92 has been implicated in the regula-
tion of IL-10 secretion by regulatory T cells [57]. Many
studies have reported links between alterations in miRNA
homeostasis and pathological conditions, such as cancer,
cardiovascular disease, diabetes, psychiatric disorders and
neurological diseases [58].
Here, we investigated the miRNA expression profile of
human natural CD8+CD25+ Treg cells and its potential
impact on Treg cell-associated functional molecules.
We focused on a subset of CD8+ Treg cells in human
cord blood, which contains a distinct population of
CD8+CD25+ Treg cells that are less heterogeneous than
in adult peripheral blood. Cord blood is useful for stud-
ies aimed at understanding human natural Treg cells
because, in contrast to adult blood, they are less contam-
inated by activated T cells that express CD25 and lack
regulatory function [59]. Therefore, we investigated the
miRNA expression profile of these natural CD8+CD25+
Treg cells and compared it with that of CD8+CD25− T
cells. Additionally, we focused our study on genes that
have been reported in the literature to be associated with
human Treg cell biology. Interestingly, we found that
some miRNAs have direct effects on FOXP3 and CTLA-
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ment and function, and also on GARP expression.
Materials and methods
Collection and preparation of cord blood samples
After approval by local and academic ethic committees
and informed consent, umbilical cord blood mono-
nuclear cells (UCBMC) were isolated from the umbilical
vein blood from normal full-term deliveries placenta.
UCBMC were isolated by appropriate centrifugation
over a lymphocyte separation medium (PAA laborator-
ies). The study was approved by the Institut Jules Bordet
scientific, and ethic committees and by the committees
of Université Libre de Bruxelles.
Isolation of T-cell populations
Cord blood CD8+ lymphocytes were purified using CD8+
T cell isolation kit (Miltenyi Biotec, Bergisch Gladbach,
Germany) according to the manufacturer protocol. Briefly,
UCBMC were first incubated in PBS supplemented with
2% heat-inactivated fetal bovine serum and saturating
amounts of biotin-conjugated antibody cocktail (anti-
CD4, CD15, CD16, CD19, CD36, CD56, CD123, TCR-γ/δ
and anti-Glycophorin A). Leucocytes were then incubated
with anti-biotin microbeads and CD8+ T cells were puri-
fied using magnetic separation columns (Miltenyi Biotec).
The negatively selected cells were incubated with anti-
CD25 micro-beads, and then CD25+ and CD25− cells
were purified from CD8+ T lymphocyte fraction using
magnetic columns (Miltenyi Biotec).
FOXP3 intracellular staining and flow cytometry
FOXP3 intracellular staining was performed using anti-
human FOXP3-PE detection Kit (BD Biosciences) fol-
lowing the manufacturer's instructions. Anti-CD3-PerCP,
anti-CD8-APC, anti-CTLA-4-PE (BD Biosciences), anti-
CD25-PE (Miltenyi Biotec) were used to assess cell
phenotype and purity. Corresponding isotype controls
served as controls. Flow cytometry analysis was per-
formed on a FACSCalibur machine with Cell Quest soft-
ware (Becton-Dickinson Biosciences).
Treg suppressive capacity assessment in Mixed Leukocyte
Reaction Assays
Treg suppressive capacity toward proliferation of activated
allogeneic carboxyfluorescein succinimidyl ester (CFSE)-
labeled T lymphocytes was assessed by flow cytometry
analysis after 5 days of co-culture experiments. Briefly,
cord blood and healthy adult blood samples were collected
after informed consent had been obtained. T lymphocytes
were immunomagnetically purified from healthy donor’s
peripheral blood mononuclear cells by positive selection
using anti-human CD3 microbeads (Miltenyi Biotec)
according to the manufacturer's instructions. These Tlymphocytes were then labeled by CFDA-SE (CellTrace-
CFSE cell proliferation kit, Invitrogen) by using 10 mM
CFDA-SE dye to stain 107 cells.
CD8+CD25+ Tregs were isolated from cord blood
mononuclear cells as described above. The purity of the
selected cells was always above 96%, as determined by
flow cytometry analysis.
Mixed leukocyte reactions (MLR) were performed by
culturing irradiated allogeneic peripheral blood mono-
nuclear cells, as stimulating cells (2 × 105), to activate
CFSE-labeled allogeneic T lymphocytes responder cells
(2 × 105), in a 48-well plate (control MLR).
CD8+CD25+ nTregs or CD8+CD25− T cells were added
to MLRs at a 1:1:1 ratio before culture in RPMI with 10%
decomplemented FBS (both from Lonza Europe, Verviers,
Belgium). After 5 days of co-culture, CFSE fluorescence
dilution was measured by flow cytometry, gating on CFSE
positive cells. Samples were run on a FACSCalibur (BD
Biosciences) and analyzed using Kaluza® Flow Cytometry
Analysis software (Beckman Coulter Inc.).
RNA extraction, RT and real-time PCR quantification
Total RNA was extracted from cells using Trizol® total
RNA isolation reagent (Invitrogen, Life Technologies,
Belgium). The concentration was quantified using a
NanoDrop Spectrophotometer. TaqMan microRNA assays
(Applied Biosystems) were used to quantify mature micro-
RNA (miR) expression. RNU44 (Applied Biosystems) was
used as endogenous control for miR expression studies.
Thus, gene-specific RT was performed for each miR
using 10 ng of purified total RNA, 100 mM dNTP, 50 U
MutliScribe reverse transcriptase, 20 U RNase inhibitor,
and 50 nM of gene-specific RT primer samples using the
TaqMan MicroRNA Reverse Transcription kit (Applied
Biosystems). Fifteen microliter reactions were incubated
for 30 min at 16°C, 30 min at 42°C, and 5 min at 85°C
to inactivate the reverse transcriptase. Real-time RT-
PCR (5 μL of RT product, 10 μL TaqMan 2× Universal
PCR master Mix, (Applied Biosystems) and 1 μL Taq-
Man MicroRNA Assay Mix containing PCR primers and
TaqMan probes) were run in triplicates at 95°C for
10 min followed by 40 cycles at 95°C for 15 s and 60°C
for 1 min.
Quantitative miR expression data were acquired and an-
alyzed using an ABI Prism 7900HT Sequence Detection
System (Applied Biosystems).
TLDA and individual quantitative PCR validation
TheTaqMan Low Density Array (TLDA, Applied Biosystems)
technique allowed us to measure the expression of 384
miRs, in order to compare the miR expression profile of
purified nTregs with their CD25− counterpart T cells ori-
ginating from five different cord bloods. cDNA was syn-
thesized from 100 ng of total cellular RNA by First Strand
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MutliScribe reverse transcriptase, 20 U RNase inhibitor,
10× RT buffer, and Multiplex RT human primer. Ten
microliter reactions were incubated for 30 min at 16°C,
30 min at 42°C, 5 min at 85°C to inactivate the reverse
transcriptase.
Five microliter cDNA were mixed with 307 μL nucle-
ase free water and 50 μL of this diluted cDNA were
mixed with 50 μL of TaqMan Universal PCR Master
Mix (Applied Biosystems). After that, 100 μL of the
sample-specific PCR mixture was loaded into one sam-
ple port, the cards were centrifuged twice for 1 min at
280 g and sealed to prevent well-to-well contamination.
The cards were placed in the Micro Fluidic Card Sample
Block of an ABI Prism 7900 HT Sequence Detection
System (Applied Biosystems). The thermal cycling con-
ditions were 2 min at 50°C and 10 min at 95°C, followed
by 40 cycles of 15 s at 95°C and 1 min at 60°C.
In each sample, average cycle threshold (Ct) values for
the target genes were subtracted from the average Ct
value of the reference gene to yield the ΔCt value. 2-ΔCt
values were calculated to indicate the relative amount of
transcripts in each sample.
For each miR that was found differentially expressed, a
validation by individual quantitative PCR was performed,
and we retained only the miR concordant with the two
techniques.
Real-time PCR
Real-time PCR quantitative mRNA analyses were per-
formed on the ABI Prism 7000 sequence detection sys-
tem using the SYBR Green fluorescence quantification
system (Applied Biosystems, Warrington, UK). The
standard PCR conditions were 95°C for 10 min, 40 cycles
for 1 min at 94°C, 56°C (1 min), and 72°C (2 min),
followed by the standard denaturation curve. The se-
quences of human primers were designed in Primer3 Input
software (version 0.4.0) and the primers were designed as
follows (Invitrogen):
β-actin,
sense: TGACAAAACCTAACTTGCGC,
antisense: ATAAAGCCATGCCAATCTCA.
IL-10,
sense: AGATCT-CCGAGATGCCTTCA,
antisense: CCGTGGAGCAGGTGAAGAAT
TGF-β,
sense: GTGGAAACCCACAACGAAA,
antisense: TAAGGCGAAAGCCCTCAATFoxp3,
sense: GAGAAGCTGAGTGCCATGCA,
antisense: GGTCAGTGCCATTTTCCCAG
CTLA-4,
sense: ATCGCCAGCTTTGTGTGTGA,
antisense: GACCTCAGTGGCTTTGCCTG
FOXO1,
sense: GCAGATCTACGAGTGGATGGT,
antisense: AAACTGTGATCCAGGGCTGTC
HELIOS,
sense: TCACAACTATCTCCAGAATGTCA,
antisense: AGGCGGTACATGGTGACTCAT
ICOS,
sense: CCATAGGATGTGCAGCCTTTG,
antisense: GGTCGTGCACACTGGATGAA
CD28,
sense: ATGCTCAGGCTGCTCCTGGCTCTC,
antisense: CAGCCGGCCGGCTTCTGGATAG
GARP,
sense: CCCTGTAAGATGGTGGACAAGAA,
antisense: CAGATAGATCAAGGGTCTCAGTGTCT
CCR4,
sense: GTGGTTCTGGTCCTGTTCAAATAC,
antisense: CGTGGAGTTGAGAGAGTACTTGGTT
IL2RA,
sense: AATGCAGCCAGTGGACCAA,
antisense: TGATAAATTCTCTCTGTGGCTTCATTT
The SYBR Green PCR master mix (Applied Biosys-
tems), 0.1–0.2 μg/μl specific primers and 2.5 ng cDNA,
was used in each reaction. Threshold for positivity of
real-time PCR was determined based on negative con-
trols. Calculations to determine the relative level of gene
expression were made according to the instructions from
the user’s bulletin (P/N 4303859) of Applied Biosystems
by reference to the β-actin in each sample, using the
cycle threshold (Ct) method. Negative controls without
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one experiment representative of three.
Cell line culture
The 293 T and HeLa cell lines were cultured in DMEM
(Lonza, Verviers, Belgium) supplemented with 10% heat
inactivated fetal bovine serum (Invitrogen Europe, Paisley,
UK), 2 mM l-glutamine, 50 IU/mL Penicillin and 50 μg/mL
Streptomycin (all from Lonza).
Plasmid construction
A 249-bp fragment of FOXP3 3′-UTR encompassing
the miR-335 potential target site and a 300-bp fragment
of CTLA-4 encompassing the miR-9 and miR-155 poten-
tial target sites were cloned downstream of the Renilla lu-
ciferase gene (Eco RI/Xho I sites) in the psiCHECK-1
plasmid (Promega, Mannheim, Germany) and designated
as psiCHECK 3′-UTR WT. PCR primers used for amplifi-
cation of the FOXP3 and CTLA-4 3′-UTR were as follows
(5′ to 3′):
FOXP3 primers:
GCGCCTCGAGTCACCTGTGTATCTCACGCATA
(forward)
GCGCGAATTCGAGCTCGGCTGCAGTTTATT
(reverse)
CTLA-4 primers:
GCGCCTCGAGAGGAGCTCAGGACACTAATA (forward)
GCGCGAATTCAATTGGGCCCATCGAACT (reverse)
QuikChange site-directed mutagenesis (deletion) of miR-
9, miR-24, miR-155 and miR-335 target sites in psiCHECK
3′-UTR WT was performed according to manufacturer's
protocols (Stratagene, La Jolla, CA) and designated as
psiCHECK-UTRdel. QuikChange site-directed mutagen-
esis were performed using the following primers (5′ to 3′):
FOXP3 (miR-335 site deleted 3′UTR):
GCCCCCCAGTGGGTGTCCCGTGCAG (forward)
CTGCACGGGACACCCACTGGGGGGC (reverse)
CTLA-4 (miR-9 site deleted 3′UTR):
GGGAATGGCACAGCAGGAAAAGGG (forward)
CCCTGCCTTTTCCTGCTGTGCCATTCCC (reverse)
CTLA-4 (miR-155 site deleted 3′UTR),
GGGATTAATATGGGGATGCTGATGTGGGTCA
AGG (forward)CCTTGACCCACATCAGCATCCCCATATTAATCCC
(reverse)
GARP 3′UTR 2070-bp encompassing the miR-24
and −335 potential target sites were cloned downstream
the Firefly luciferase gene (AsiSI/Xho1 sites) in the pEZX-
MT01 plasmid (Labomics, Nivelles, Belgium) and de-
signed as pEZX-MT01 3′-UTR WT. PCR primers used
for amplification of the FOXP3 and CTLA-4 3′-UTR were
as follows (5′ to 3′):
GARP primers:
CTCGAGAGAAGCCGGGAGAC (forward)
CCGCGGACATTCAGGTAGG (reverse)
QuikChange site-directed mutagenesis were performed
using the following primers (5′ to 3′):
GARP (miR-24 site deleted 3′UTR),
GCCCCACCTTGGCTGCAGGAGCTAAAACC
(forward)
GGTTTTAGCTCCTGCAGCCAAGGTGGGGC
(reverse)
GARP (miR-335 3′UTR site deleted),
GGGTTCTCCTGTTCTCTCTGTCATTCTCTCATT
CCC (forward)
GGGAATGAGAGAATGACAGAGAGAACAGGAGA
ACCC (reverse)
The constructs were verified by sequencing (GATC
Biotech, Konstanz, Germany).
Luciferase assays
Luciferase assays were conducted in a 24-well format.
Reporter plasmids (psiCHECK, psiCHECK 3′-UTR WT,
psiCHECK 3′-UTR deleted, pEZX-MT01, pEZX-MT01
3′-UTR GARP WT, pEZX-MT01 GARP 3′-UTR deleted)
(100 ng) were co-transfected in HEK293T and HeLa cells
along with miR-9, miR-24, miR-155, and miR-335-mimic/
miR-negative control-mimic at a final concentration of
10 μM (mirVana miRNA mimic, Life Technologies, Gent,
Belgium) and control firefly plasmid pGL3-CMV for the
psiCHECK vectors only (100 ng) using Lipofectamine
2000 (Invitrogen) according to the manufacturer's guide-
lines. Before proceeding to the transfection assays, the
cell lines were assessed for expression of the miR of inter-
est using quantitative RT-PCR, as described below. 24 h
post-transfection, cells were harvested, and luciferase
levels were measured using the Dual-Luciferase reporter
assay system (Promega Benelux BV, Leiden, The Netherlands)
according to the manufacturer's guidelines. Relative protein
Jebbawi et al. Journal of Translational Medicine 2014, 12:218 Page 6 of 16
http://www.translational-medicine.com/content/12/1/218levels were expressed as Renilla/firefly luciferase ratios.
Relative protein levels were expressed as Renilla/firefly lu-
ciferase ratios in case of co-transfections with psiCHECK
and PGL3-CMV vectors and firefly/Renilla for transfec-
tions with pEZX-MT01 vectors.
Lentiviral vector production
VSV-G pseudotyped lentiviral particles were generated by
polyethyleneimine (Sigma) co-transfection of HEK293T
cells with three plasmids, pMIRNA, pCMVΔR8.91, and
pMD.G [60].
pCMVΔR8.91 is an HIV-derived packaging construct
that encodes the HIV-1 Gag and Pol precursors as well
as the regulatory proteins Tat and Rev [61]. VSV-G was
expressed from pMD.G [62]. pMIRNA, provided by Sys-
tem Biosciences, is a lentivirus-based vector in which a
microRNA precursor molecule has been cloned down-
stream of the CMV promoter and contains copGFP as a
reporter gene. 24 h after transient transfection of HEK293T
cells, viral supernatants were collected, filtered through
0.45-μm low protein-binding filters (Nalgene, Rochester,
NY), and concentrated as described previously [63]. The
viral pellets were then resuspended in 1/100 volume of
PBS. Viral stocks were stored in aliquots at −80°C, and the
titers were determined by transducing HeLa cells in a limit-
ing dilution assay. Lentiviral vector preparations collected
24 h post-transfection, and after concentration, displayed
titers of 108–109 transducing units/ml in HeLa cells. No
replication-competent virus was detected in the concen-
trated lentiviral stocks. A second production cycle was re-
peated after 24 h, routinely generating lentiviral vector
preparations of 5 × 107 to 5 × 108 transducing units/ml.
Lentiviral transduction
Tregs were plated at a density of 106 cells/well in 12-
well tissue culture plates in 1 ml of RPMI 1640 supple-
mented with 10% heat-inactivated fetal bovine serum,
2 mM L-glutamine, 50 units/ml penicillin, 50 μg/ml
streptomycin (Lonza), in the presence of 5 μg/ml phyto-
hemagglutinin (PHA-L, Sigma) and 20 units/ml IL-2.
24 h after Treg isolation, cells were exposed to lenti-
viral vector preparation at a multiplicity of infection of
5 in a volume of 500 μl in the presence of 8 μg/ml poly-
brene (Sigma). GFP-positive cells were sorted by flow
cytometry at day 7 after transduction.
MiR-9, miR-24, miR-155 and miR-335 detection by TaqMan
Real-time PCR
TaqMan miRNA assays (Applied Biosystems) used the
stem loop method [64,65] to detect the expression level
of mature miR-9, miR-24 miR-155 and miR-335. For RT
reactions, 10 ng of total RNA was used in each reaction
(15 μl) and mixed with the RT primer (3 μl). The RT re-
action was carried out under the following conditions:16°C for 30 min, 42°C for 30 min, 85°C for 5 min, and
then holding at 4°C. After the RT reaction, the cDNA
products were diluted at 5×, and 9 μl of the diluted
cDNA was used for PCR along with the TaqMan micro-
array assay (1 μl) and PCR master mix (10 μl). The PCR
was conducted at 95°C for 10 min, followed by 40 cycles
of 95°C for 15 s and 60°C for 60 s in the ABI 7900 real-
time PCR system. The real-time PCR results were ana-
lyzed and expressed as relative miRNA expression of Ct
value, which was then converted to -fold changes. RT
primer, PCR primers, and TaqMan probe for miR-9,
miR-24, miR-155 and miR-335 were purchased from
ABI. RNU48 was used for normalization.
Quantitative PCR for FOXP3, CTLA-4 and GARP expression
Total RNA was extracted with Trizol reagent according
to the manufacturer's guidelines (Invitrogen), and first-
strand cDNAs were synthesized by reverse transcription
(Superscript First-strand Synthesis System for RT-PCR
kit, Invitrogen) Quantitative mRNA expression was mea-
sured by real-time PCR with the PRISM 7900 sequence
detection system (Applied Biosystems), and the TaqMan
master mix kit; EF1-α mRNA was used as an internal
control. Human TaqMan gene expression assay for FOXP3
(Hs01085834-m1), CTLA-4 (Hs03044418-m1), GARP
(Hs0019436-m1) and EF1-α (Hs01024875-m1) were pur-
chased from Applied Biosystems. The program used for
amplification was as follows: 10 min at 95°C followed by
40 cycles of 15 s at 95°C, 1 min at 60°C.
Statistical analysis
Data are presented as means ± SD of at least three inde-
pendent experiments and analyzed using Student's t test.
p values of <0.05 (*), <0.01 (**), and <0.001 (***) were
considered significant.
Results
CD8+CD25+ natural Treg cells express FOXP3 and CTLA-4
CD8+CD25+ and CD8+CD25− T cells were immunomag-
netically purified from fresh human cord blood by nega-
tive selection of CD8+ T cells, followed by CD25-based
positive selection (Miltenyi Biotec, Bergisch Gladbach,
Germany). To confirm the purity of the separated cell
fractions, CD8+CD25+ and CD8+CD25− T cells were an-
alyzed by flow cytometry. Purity was always >96%. CD8+
natural Treg cells expressed more intracellular FOXP3
and cell-surface CTLA-4 proteins compared with CD8+
CD25− T cells (Figure 1).
CD8+CD25+ natural Treg cells are suppressive
In vitro Treg cell suppression assays were performed to
assess the functional impact of the isolated Treg cells on
activated T cell proliferation. CD8+CD25+ natural Treg
cells suppressed allogeneic mixed leukocyte reactions
Figure 1 Purified human CD8+CD25+ natural Tregs express FOXP3 and CTLA-4. Separated cell fractions, CD8+CD25+ and CD8+CD25− T
cells, were analyzed by multicolor FACS using the following antibodies: anti-CD3 PerCP, anti-CD8-APC (BD biosciences) and anti-CD25-PE (Miltenyi
Biotec) to assess purity for each isolation. Intracellular FOXP3 and cell-surface CTLA-4 were assessed using human anti-FOXP3-PE detection kit and
anti-CTLA-4-PE (BD biosciences). Flow cytometry was performed using a FACSCalibur applying CellQuest software (BD Biosciences). CD3 and CD8
purity was above 97% among isolated CD8+ T cells. CD8+CD25+ nTregs express FOXP3 and CTLA-4 when compared to CD8+CD25− T cells.
Jebbawi et al. Journal of Translational Medicine 2014, 12:218 Page 7 of 16
http://www.translational-medicine.com/content/12/1/218when measured at day 5, as indicated by CFSE dilution
of CD3+ T cells. Our analysis (Figure 2) indicated that
CD8+CD25+ natural Treg cells could inhibit allogeneic
T cell proliferation.
Assessment of Treg cell-related gene expression in
CD8+CD25+ and CD8+CD25− T cells qPCR
The mRNA transcript levels were analyzed by qPCR to
compare CD8+CD25+ with CD8+CD25− T cells using
SYBR green detection. Importantly, we showed (Table 1)
that IL-2RA, FOXP3, CTLA-4, CCR4, GARP, IL-10 and
TGF-β were upregulated in CD8+CD25+ natural Treg cells
compared with CD8+CD25− T cells, whereas CD28, ICOS,
FOXO1 and HELIOS were downregulated in CD8+CD25+
natural Treg cells compared with CD8+CD25− T cells.
The CD8+CD25+ natural Treg cell microRNA signature
We first studied miRNAs from five independent CD8+CD25+
natural Treg cell and CD8+CD25− T cell samples using
the TLDA technique. We could identify several miRNAs
that were differentially expressed between CD8+CD25+
natural Treg cells and CD8+CD25− T cells. Differentially
expressed miRNAs were validated by real-time PCR
(Figure 3). A Treg cell miRNA signature was identifiedthat included 10 significantly differentially expressed miR-
NAs: miR-9, −24, −31, −155, −210, −335 and −449 were
downregulated in CD8+ natural Treg cells, whereas
miR-214, −205 and −509 were overexpressed.
Target prediction for miR-9, −24, −155 and −335
Computer-based programs were used to predict potential
targets sites for the miRNAs that were associated with
downregulation in the FOXP3 and CTLA-4 3′-UTRs. We
searched miRBase [66] and TargetScan 4.2 [67]. We could
identify putative miRNA target sites in the FOXP3 and
CTLA-4 3′-UTRs by both programs—miR-335 in the
FOXP3 3′-UTR and both miR-9 and −155 in the CTLA-4
3′-UTR. Furthermore, miR-31, −24, −210 and −335 have
target sites in the FOXP3 3′-UTR but not in the CTLA-4
3′-UTR, while miR-9 and −155 have target sites in the
CTLA-4 3′-UTR but not in the FOXP3 3′-UTR [68,69].
FOXP3 is directly regulated by miR-335
A 249-bp fragment of the 3′-UTR of FOXP3 containing the
miR-335 target sequence was cloned into a psiCHECK-1
vector downstream of the Renilla luciferase gene (psi-
CHECK-UTRwt). In parallel, in the same way we cloned
this FOXP3 3′-UTR fragment with a deleted miR-335
Figure 2 Functional assessment of CD8+CD25+ nTreg cell suppressive capacity toward proliferation of allogeneically activated
CFSE-labeled T lymphocytes. CFSE dilution analysis shows CD8+CD25+ nTreg-mediated suppression of allogeneic T cell proliferation in 5 days
mixed leukocyte reaction (MLR) compared to control MLR and compared to MLR with CD8+CD25− non-Tregs. CFSE dilution histograms are shown
for 1:1 suppressor/responder cell ratio. Shown is one representative experiment out of four independent experiments performed. (A) CFSE-labeled
allogeneic T cells alone at d0 before MLR. (B) Proliferation of CFSE-labeled allogeneic T cells after 5 days of allo-MLR (control MLR). (C) Allo-MLR in
presence of CD8+CD25− non-Treg cells, at day 5. (D) Allo-MLR in presence of CD8+CD25+ nTregs, at day 5.
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of psiCHECK-UTRwt or psiCHECK-UTRdel in HEK293T
cells led to no significant change in reporter luciferase ac-
tivity when compared with the psiCHECK control vector
(Figure 4A). By contrast, co-transfection of HEK293T cells
with miR-335 and psiCHECK-UTRwt led to a significant
reduction (~47%) in relative reporter luciferase activity,
and also for activity compared with the co-transfection of
HEK293 T cells with miR-Ctrl and psiCHECK-UTRwt.Table 1 Relative regulatory T cell-associated gene expression f
Relative Treg-associated gene expression
Gene IL2RA FOXP3 CTLA-4
CD8 + CD25+/CD8 + CD25- 65 ± 1,414 11,5 ± 4,9 3.19 ± 1
Gene CD28 ICOS FOXO1
CD8 + CD25+/CD8 + CD25- 0,05 ± 0,019 0,342 ± 0,125 0,18 ± 0
Gene mRNA levels were evaluated using quantitative RT-PCR of CD8+CD25+/CD8+C
each done in triplicate.Together, these results demonstrate a specific role for
miR-335 in the regulation of FOXP3 expression through
direct binding to its target site.
CTLA-4 is directly regulated by miR-9 and miR-155
We next investigated whether CTLA-4 could be directly
targeted by miR-9 and −155. We engineered luciferase
reporter plasmids containing either the wild-type 3′-
UTR of this gene (psiCHECK-UTRwt) or a 3′-UTR withor CD8+CD25+/CD8+CD25− by individual qPCR (SYBR Green)
CCR4 GARP IL10 TGF-B
,73 13.43 ± 4,69 13,66 ± 4,12 4.86 ± 2,68 4.57 ± 2,61
HELIOS
,078 0,288 ± 0,13
D25− T cells. Data represent the mean ± SD of five independent experiments,
Figure 3 Differential expression of miR-24, −335, −155, −31, −210, −449, −509, −214, −205 and −9 between CD8+CD25+ nTregs and
CD8+CD25− T cells. Data obtained by qRT-PCR amplification of miRs are plotted. p values for each miRNA relative expression are presented. Boxes
represent SE; and Error bars SD Pooled data from five independent experiments are shown. (*p < 0.05; **p < 0.01 CD8+CD25+ nTregs versus
CD8+CD25− T cells (Student's t test).
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del). We found that co-transfection of HEK293 T cells
with miR-9 and psiCHECK-UTRwt led to a reduction
(~52%) in reporter luciferase activity compared with the
co-transfection of HEK293 T cells with miR-9 and
psiCHECK-UTRdel or the co-transfection of HEK293 T
cells with miR-Ctrl and either psiCHECK-UTRwt or
psiCHECK-UTRdel (Figure 4B).
Similarly, the co-transfection of HEK293 T cells with
miR-155 and psiCHECK-UTRwt led to a significant re-
duction (~65%) in reporter luciferase activity, while
there was no difference observed for the co-transfectionof HEK293 T cells with miR-155 and psiCHECK-UTRdel
or for the co-transfection of miR-Ctrl and either
psiCHECK-UTRwt or psiCHECK-UTRdel. Moreover,
the co-transfection of HEK293 T cells with psiCHECK-
UTRwt and both miR-9 and −155 led to a reduction
(~65%) in reporter luciferase activity, but this reduction
was not greater than that achieved using miR-155 alone,
suggesting that either miR-155 or −9 alone could achieve
robust downregulation of CTLA-4.
Altogether, these results demonstrate the roles of miR-9
and −155 in the regulation of CTLA-4 expression through
direct and specific binding to their target sites.
Figure 4 MicroRNA specific activities. (A) MiR-335 negatively regulates luciferase expression in a plasmid coupling its coding sequence with FOXP3
3′UTR. Renilla luciferase reporter assays with constructs holding FOXP3 3′-UTR sequences from the indicated genes were co-transfected into HEK293T cells
along with a firefly luciferase transfection control plasmid either alone or together with miR-335. (B) MiR-9 and miR-155 negatively regulate luciferase
expression in a plasmid coupling its coding sequence with CTLA-4 3′UTR. Renilla luciferase reporter assays with constructs holding CTLA-4 3′-UTR
sequences, wild type or miR-site deleted, were co-transfected into HEK293T cells along with a firefly luciferase transfection control plasmid either alone
or together with miR-9, −155. MiR-24 (C) and miR-335 (D) specifically targets GARP 3′UTR and negatively regulate luciferase reporter expression. Renilla
and firefly luciferase reporter assays with constructs holding GARP 3′-UTR sequences, wild type or miR-site deleted, were co-transfected into HEK293T cells
along with miR-24, −335. Relative luciferase values normalized to transfections without miRNA are shown. Data represent mean ± SD (error bars) of three
independent experiments, each performed in triplicate. (*p < 0.05; **, p < 0.01, Student's t test).
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Analysis of reporter luciferase activity in HEK293 T cells
co-transfected with the GARP 3′-UTR, wild-type or
miRNA site-deleted, and either miR-24 (Figure 4C) or
miR-335 (Figure 4D), showed a direct and specific tar-
geting of the GARP 3′-UTR by these miRNAs, leading
to reduced luciferase expression.
Lentiviral expression of miR-335 in fresh Treg cells
significantly reduces FOXP3 transcription
To study the effect of over-expression of miR-335 in
Treg cells, specifically on FOXP3 expression, lenti-miR-335 was used to transduce Treg cells (Figure 5); trans-
duced Treg cells were FACS-sorted based on GFP posi-
tivity. The miR-335 levels in lenti-miR-335-transduced
Treg cells were significantly higher than in lenti-miR-ctrl
transduced cells, whereas the levels of miR-335 were
two-fold lower in Treg cells compared with their nega-
tive counterparts (Figure 6A). The control for each
miRNA transduction was a scrambled miR sequence.
Clearly, the expression levels of miR-335 in transduced
Treg cells were higher than the physiological level ob-
served in non-Treg cells, but this resulted from our in-
ability to adjust the levels of expression of the transgene.
Figure 5 Differential expression of miR-24, −335, −155 and −9 in CD8+CD25+ natural Treg cells after transduction by lenti-miR-24,
−335, −155 and −9. Data obtained by qRT-PCR amplification of miRs are plotted for CD8+CD25+nTregs versus non-transduced CD8+CD25+
nTregs. p values for each miRNA relative expression are presented. Boxes represent SE; and Error bars SD. Pooled data from five independent
experiments are shown. (*p < 0.05; **p < 0.01 Student's t test).
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down-regulate FOXP3 expression, although not to the
level of non-Treg cells, demonstrating that FOXP3 ex-
pression must be controlled by combined inputs from
several pathways, including miR-335. Additionally, the
levels of FOXP3 were 3.19-fold lower in lenti-miR-31
transduced cells compared with lenti-miR-ctrl and non-
transduced cells [68]. These results demonstrate that
FOXP3 expression is controlled by miR-335.
Lentiviral transduction of miR-9 and −155 in Treg cells
significantly reduces CTLA-4 expression
To study the effect of miR-9 and −155 on the mRNA ex-
pression levels of CTLA-4, we increased miR-9 and −155
levels by expressing the miR-9 and −155 precursors froma lentiviral vector (lenti-miR-9 and −155). After lenti-
miR-9 and −155 viral transduction (Figure 5), we found
that the mRNA levels of CTLA-4 decreased (2.02-fold)
in the lenti-miR-9-transduced Treg cells compared with
the lenti-miR-ctrl transduced cells and the mRNA levels
of CTLA-4 decreased (2.79-fold) in the lenti-miR-155
transduced Treg cells compared with the lenti-miR-ctrl
transduced cells (Figure 6B).
Lentiviral transduction of miR-24 and −335 in Treg cells
significantly reduces GARP expression
Efficient ex vivo transduction of Treg cells using lenti-
miR-24 and lenti-miR-335 (Figure 5) showed that miR-24
and −335 expression significantly reduced GARP expres-
sion levels by 3.21- and 1.96-fold, respectively (Figure 6C).
Figure 6 MicroRNA specific activities. (A) In primary human Treg
cells, miR-335 specifically regulates FOXP3 expression. Relative
miR-335 and FOXP3 expression in CD8+CD25+ Treg cells transduced
by lenti-miR-335 compared with CD8+CD25+ Treg cells transduced
by lenti-miR-Ctrl, as determined by relative qRT-PCR. (B) In primary
human Treg cells, miR-9 and −155 specifically regulate CTLA-4
expression. Relative miR-9, miR-155 and CTLA-4 expression in
CD8+CD25+ Treg cells transduced by lenti-miR-9 or lenti-miR-155
compared with CD8+CD25+ Treg cells transduced by lenti-miR-Ctrl,
as determined by relative qRT-PCR. (C) In primary human Treg cells,
miR-24 and −335 specifically regulate GARP expression. Relative
miR-24 and GARP expression in CD8+CD25+ Treg cells transduced by
lenti-miR-24 compared with CD8+CD25+ Treg cells transduced by
lenti-miR-Ctrl, as determined by relative qRT-PCR. Relative miR-335
and GARP expression in CD8+CD25+ Treg cells transduced by
lenti-miR-335 compared with CD8+CD25+ Treg cells transduced by
lenti-miR-Ctrl. as determined by relative qRT-PCR. CD8+CD25− T cells
were considered to be non-Tregs; *p < 0.05, **p < 0.01, ***p < 0.001
(as determined by Student's t-test).
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We previously described a miRNA signature in human
natural CD4+ Treg cells. We could also identify a miRNA
signature in CD4+CD25+CD127low Treg cells from periph-
eral blood. Importantly, for both signatures, we could
show how the described miRNAs specifically regulate
genes associated with Treg cell function in human primary
T cells [68,69].
Here, we purified CD8+CD25+ natural Treg cells from
human cord blood, assessed FOXP3 and CTLA-4 expres-
sion by flow cytometry and measured mRNA levels using
quantitative PCR. As expected, FOXP3 and CTLA-4 pro-
tein and mRNA levels were increased in the CD8+CD25+
natural Treg cells compared with CD8+CD25− T cells.
Importantly, those cells showed suppressive properties
ex vivo in a mixed T cell reaction in which irradiated allo-
geneic PBMCs were used as stimulators.
Reviewing the Treg cell literature, we identified a list of
genes known to play an important role in the regulation
of Treg cell function and development. We investigated
the relative expression of these genes in CD8+CD25+ nat-
ural Treg cells compared with CD8+CD25− T cells using
qPCR. We found that expression of the FOXP3, CTLA-4,
CCR4, GARP, IL-10 and TGF-β genes was upregulated in
CD8+CD25+ natural Treg cells, whereas the CD28, ICOS,
FOXO1 and HELIOS genes were underexpressed. Obvi-
ously, IL2RA (CD25) was found to be overexpressed by
these Treg cells. Overall, these results further support the
regulatory features and potential of these cells.
Using TaqMan low-density arrays and quantitative PCR
confirmation of selected transcripts, we could define the
first miRNA ‘signature’ for human purified CD8+CD25+
natural Treg cells. This ‘signature’ included 10 significantly
differentially expressed miRs: miR-214, −205 and −509 were
overexpressed, whereas miR-9, −24, −31, −155, −335, −210
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Treg cells compared with CD8+CD25− Tcells.
Next, we investigated the potential role of the miRNAs
from this signature on the expression of genes related to
Treg cell function and development. We found that the
3′-UTR of FOXP3 contained miRNA target sites for
miR-24, −31, −210 and −335, which were all underex-
pressed in CD8+CD25+ natural Treg cells compared with
CD8+CD25- T cells. Scanning the 3′-UTR of CTLA-4
revealed that miR-9 and −155 (both underexpressed in
Treg cells) contained a target site. Similarly, we found
miR-24 and miR-335 target sites in the GARP 3′-UTR.
Although not Treg cell-specific, FOXP3 remains the
best-known transcription factor that specifically orches-
trates a transcriptional program that is required for the
establishment, maintenance and function of the Treg
cell lineage.
Importantly, we have previously shown that miR-24,
miR-210 and miR-31 [68,69] negatively regulate the ex-
pression of FOXP3 in human T cells. Interestingly, using
3′-UTR cloning, site-directed mutagenesis and miRNA co-
transfection experiments, we demonstrated that miR-335
negatively regulates FOXP3 expression in a direct and
specific manner. Moreover, transducing lenti-miR-335
in natural Treg cells leads to the negative regulation of
FOXP3 expression compared with lenti-miR-Ctrl trans-
duced cells. Importantly, four out of the seven underex-
pressed miRNAs in the CD8+ natural Treg cell miRNA
‘signature’ can regulate FOXP3 expression in primary
Treg cells.
Many studies have focused on the role of CTLA-4 ex-
pression in Treg cells. Kolar et al. showed that CTLA-4
had an important function in Treg cell homeostasis and
also highlighted the importance of CTLA-4 in the in vivo
suppressive mechanism employed by Treg cells. These
findings have identified CTLA-4 as a crucial costimulator
of Treg cells by demonstrating its role in mediating the re-
sistance of Treg cells to activation-induced cell death [70].
Additionally, CTLA-4 expression and signaling are essen-
tial for Treg cells to execute their suppressive function
in vivo. Moreover, CTLA-4 has been described to play a
negative role in tumor progression or persistence. These
findings have brought several groups, including Jim
Allison’s group, to work on anti-CTLA-4 antibodies for
cancer immunotherapy that have already shown very
promising clinical results [70]. Considering the important
role of CTLA-4 in Treg cell biology, we decided to investi-
gate the effect of miR-9 and −155 (underexpressed in
CD8+ natural Treg cells) on CTLA-4 expression. Using
the same strategy as we did for FOXP3, we carried out
CTLA-4 3′-UTR cloning, site-directed mutagenesis and
miRNA co-transfection experiments with a reporter lucif-
erase activity assay and lentiviral-mediated microRNA
transduction of primary natural Treg cells. We could showthat both miR-9 and −155 negatively regulate CTLA-4
expression in a direct and specific way. Recently, miR-155
was shown to be overexpressed in tissues of patients
with atopic dermatitis, associated with inflammatory
CD4+ T cells and capable of targeting CTLA-4. This
study supports our findings by suggesting that miR-155
underexpression in CD8+ natural Treg cells contributes
to the regulation of CTLA-4 expression.
GARP received significant attention from the immune
regulation field, as it is naturally produced by Treg cells
and has the capacity to present latent TGF-β on the Treg
cell surface. Very recently, Skapenko’s group showed that
miR-142-3p targeted GARP in CD4+CD25+ T cells [55]
and Sophie Lucas’ group described that GARP is regulated
by microRNAs (miR-142-3p, −181a and −185) and con-
trols latent TGF-β production by human CD4+ Treg
cells [71]. Our experiments show that miR-24 and −335
specifically bind to the GARP 3′-UTR and directly regu-
late GARP expression in primary human CD8+ natural
Treg cells.
With great interest, we noticed the relatively high num-
ber of potential target sites for miRNAs in the signature
that were found in many genes relevant to Treg cell biol-
ogy. However, additional work will be required to prove
that these miRNAs effectively regulate these genes.
In parallel, it is also interesting to note that the major-
ity of miRNAs in the CD8+CD25+ natural Treg cell sig-
nature are also found to be differentially expressed in
either the CD4+CD25+ natural Treg cell (miR-31) or the
circulating peripheral blood CD4+CD25+CD127low Treg
cell (miR-9, −24, −210, −335 and −509) signatures, which
may suggest that a limited number of miRNAs control the
expression of major features of Treg cells. While subpopu-
lations of Treg cells that our group has studied do not
encompass all human Treg cells described, they likely
cover the vast majority of them.
Conversely, the miRNAs that are not shared by several
Treg cell subpopulations could condition, or be condi-
tioned by, phenotypic or functional differences between
types of regulatory cells. In this sense, miR-155 appears
in our miRNA signature to be more closely linked to
CD8+ natural Treg cells. It appears that miR-155 has an
important role in the immune system. Romero’s group
described a specific important role for miR-155, in mice
and humans, in the maturation of CD8+ T cells from a
naive to effector state and in their further acquisition of
cytolytic properties; both processes correlated with high
expression of miR-155 [72]. Our observation that miR-155
targets CTLA-4 in CD8+ T cells can extend the insights
provided by this group, suggesting an additional role for
miR-155 that not only coordinates the expression of the
machinery elements needed for cytotoxicity, but also con-
trols some immunosuppressive molecules during the
effector phase of the cellular immune response.
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man Treg cells, different microRNAs can target the 3′-UTR
of the same gene (FoxP3 is targeted by miR-24, −31, −210
and −335, CTLA-4 is targeted by miR-9 and −155, and
GARP is targeted by miR-24 and −335). Furthermore, a
defined miRNA can target several genes important for
Treg cells, suggesting a high level of coordination between
miRNAs for the efficient regulation of a target gene or
function. Our findings also suggest the existence of a ‘pro-
gram’ carried out by a single miRNA that targets a set of
genes associated with a type of activity.
All of these observations emphasize the importance of
miRNA-mediated regulation of complex biological processes.
Caution should be taken when comparing miRNA sig-
natures because they are always generated by relative
comparisons to a cell type that is chosen and described
as the negative counterpart of the cell population stud-
ied. This implies that a signature may vary when one
swaps the cell taken as a ‘counterpart’. Therefore, it is
crucial not to limit oneself to the study of how miRNAs
affect the expression of a reporter gene transfected in a
cell line, but rather to look at the biological relevance of
the signature in the corresponding fresh primary Treg
cells using transduction by a vector expressing the
miRNA of interest compared with a control vector.
Conclusions
We have identified an easy and convenient source of hu-
man CD8+CD25+ natural Treg cells and confirmed they
share key known features of Treg cells. We reported for
the first time the microRNA signature of these cells.
Moreover, we found an essential role for six miRNAs
out of 10 found in the signature, suggesting that this sig-
nature is directly relevant for Treg biology. The hypoth-
esis that different signatures modulate distinct aspects of
regulatory function should be explored. We are currently
studying the role of these under- and overexpressed miR-
NAs to identify new target genes implicated in the direct
or indirect control of Treg cell biology. While much work
still needs to be done to better understand the overall
regulation of Treg cell functions, this study underlines the
importance of miRNAs in this area and the chance that
they offer to explore new therapeutic targets in immune
disorders, infectious diseases and cancers.
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